# Deucravacitinib for the treatment of moderate-to-severe palmoplantar pustulosis: Results from an early-terminated open-label trial

**Authors:** Ravi Ramessur, Zelma C. Chiesa Fuxench, Daniel Shin, Jennifer B. Mason, Anabel C. Mason, Maryte Papadopoulos, Bruna Galvao de Oliveira Wafae, Megan H. Noe, Joel M. Gelfand

PMC · DOI: 10.1016/j.jdin.2025.09.015 · 2025-10-09

## Full-text entities

- **Diseases:** palmoplantar pustulosis (MESH:D011565)
- **Chemicals:** Deucravacitinib (MESH:C000628674)

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12805082/full.md

---
Source: https://tomesphere.com/paper/PMC12805082